相关实验视频

Updated: Jun 21, 2025

Induction and Testing of Hypoxia in Cell Culture

Induction and Testing of Hypoxia in Cell Culture

Published on: August 12, 2011

l-2-Hydroxyglutarate通过调节缺氧诱导因子-1α信号通路,促进瘤的放射电阻

Manman Zhang^1,2,3,4, Yingshuang Liu^1,2,3,4, Xinran Lu^1,2,3,4

¹Institute of Radiation Medicine, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, China.

Journal of cellular physiology

|July 16, 2024

概括

l-2-Hydroxyglutarate (l-2-HG) 通过减少DNA损伤和促进细胞存活来增强瘤的放射电阻. 这种代谢物上调低氧诱导因子-1α (HIF-1α),影响癌症的进展和患者的结果.

科学领域:

代谢学代谢学代谢学
癌症生物学癌症生物学
分子瘤学分子瘤学

背景情况:

l-2-Hydroxyglutarate (l-2-HG) 是一种已知的瘤代谢物,与缺氧适应有关.
l-2-HG在瘤电阻中的特定作用及其机制在很大程度上仍未被探索.

研究的目的:

为了研究l-2-HG对人类质母细胞细胞中放射电阻的影响.
阐明l-2-HG影响放射电阻的潜在分子机制.

主要方法:

人类质母细胞细胞被用l-2-HG处理并接受辐射.
对DNA损伤,细胞亡,细胞增殖,迁移和细胞周期进展的分析.
西方涂抹和基因表达分析,以评估缺氧诱导因子-1α (HIF-1α) 和其下游目标.
在体内研究中,使用裸体小鼠,在L2HGDH基因被淘汰后移植U87细胞.
对L2HGDH基因表达与患者生存数据的相关性分析.

主要成果:

l-2-HG为U87细胞提供了放射电阻,减少了辐射引起的DNA损伤和亡.
l-2-HG促进了细胞增殖和迁移,同时损害了G2/M阶段停止.
l-2-HG上调HIF-1α蛋白水平及其下游目标基因表达.
通过增加HIF-1α,抑制L2HGDH增强了体内瘤生长和扩散.
低L2HGDH表达与质瘤和癌患者的生存率较差相关.

结论:

l-2-HG在促进瘤放射电阻方面发挥着重要作用.
该机制涉及HIF-1α通路的上调.
L2HGDH表达是一种潜在的预后生物标志物,向l-2-HG代谢可以提供针对瘤放射电阻的新策略.

关键词:

U87人类质母细胞细胞质瘤或癌可能是瘤或癌.缺氧诱导因子-1α信号通路一-2-基质酸盐.瘤的辐射电阻.

更多相关视频

Author Spotlight: Exploring Salidroside's Molecular Mechanisms in Breast Cancer Treatment

Author Spotlight: Exploring Salidroside's Molecular Mechanisms in Breast Cancer Treatment

Published on: June 9, 2023

Co-immunoprecipitation Assay Using Endogenous Nuclear Proteins from Cells Cultured Under Hypoxic Conditions

Co-immunoprecipitation Assay Using Endogenous Nuclear Proteins from Cells Cultured Under Hypoxic Conditions

Published on: August 2, 2018

相关概念视频

Regulation of Angiogenesis and Blood Supply

Regulation of Angiogenesis and Blood Supply

Rapidly dividing tumors, embryos, and wounded tissues require more oxygen than usual, lowering the oxygen concentration in the blood. At low oxygen or hypoxic conditions, an oxygen-sensitive transcription factor called the hypoxia-inducible factor 1 or HIF1 is activated. HIF1 is a dimeric protein of alpha (ɑ) and beta (β) subunits. Under optimal oxygen conditions, HIF1β is present in the nucleus while HIF1ɑ remains in the cytosol. HIF1ɑ is hydroxylated by prolyl...

Adaptive Mechanisms in Cancer Cells

Adaptive Mechanisms in Cancer Cells

Cancer cells accumulate genetic changes at an abnormally rapid rate due to the defects in the DNA repair mechanisms. From an evolutionary perspective, such genetic instability is advantageous for cancer development. Mutant cell lines accumulate a series of beneficial mutations that contribute to their progression into cancer.
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...

mTOR Signaling and Cancer Progression

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...

Treatment Resistant Cancers

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...

Cancer Therapies

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...